US EditionUCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
- On June 12, 2025, UCB, a global biopharmaceutical company, revealed plans to invest $5 billion in constructing a cutting-edge biologics production plant in the United States.
- This investment follows UCB’s long-term growth in the US market, driven by $4.5 billion in acquisitions since 2017 and 15 FDA approvals over eight years.
- The company is conducting a feasibility study to select a location offering strong talent pipelines and innovation ecosystems, aiming to create 300 permanent and 500 construction jobs.
- CEO Jean-Christophe Tellier emphasized that increasing their biologics manufacturing capacity not only strengthens their global supply chain but also supports advanced medical research, creates skilled employment opportunities, and promotes sustained economic growth within the United States.
- The new facility will reinforce UCB’s global supply chain, support its expanding pipeline, and reflect its commitment to scientific innovation and sustainable healthcare value in the US.
14 Articles
14 Articles
The Belgian chemical and biopharmaceutical company multiplies investments. ...
Observer News Enterprise
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Committed to serve U.S. patients and deliver economic impact of approximately $5 billion, including creation of 300 U.S. direct high skilled jobs and more than 500 construction jobsScaling up U.S. based Contract Manufacturing Organization (CMO) partnerships to support the growth…
Biologics for Ulcerative Colitis: What Are the Pros and Cons?
Over the past 15 years, treatment options for ulcerative colitis (UC) , a type of inflammatory bowel disease, have expanded quite a bit. Among the most common options is a class of drugs called biologics . Biologics are derived from natural sources, such as human or animal genes or microorganisms, and are designed to act on the immune system, specifically the parts that play key roles in fueling inflammation.e60dc2a1-f33c-4a05-9b50-8e3e8e5976297…
19:00 To keep up with strong growth, Belgian pharmaceutical company UCB is investing $2 billion over the next six to seven years in a new production facility in the United States, its most important market...
Coverage Details
Bias Distribution
- 83% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
